Xavier Jacq

Xavier Jacq has a diverse and extensive work experience spanning several prestigious companies in the biotechnology and pharmaceutical industries.

Xavier is currently serving as the Chief Scientific Officer at MoA Technology since December 2022.

Prior to that, Xavier held a position as an Honorary Senior Lecturer at Queen's University Belfast since April 2019.

Xavier also worked as the Senior Vice President at Dunad Therapeutics from January to December 2022.

From June 2018 to January 2022, Xavier served as the VP Biology at Almac Discovery.

Xavier also held the role of Director at Cambridge Discovery Consultancy Ltd from December 2017 to January 2022.

Before that, they worked as a Senior Consultant at CamPhos Therapeutics from February 2017 to June 2018.

From October 2015 to August 2016, Xavier held the position of VP Scientific Affairs at MISSION Therapeutics. Xavier also served as the VP Biology and co-founder at the same company from April 2011 to August 2016, where they were involved in team management, project management, IP management, and other responsibilities.

Xavier's career also includes a role as a Team Leader and Project Leader at KuDOS Pharmaceuticals-AstraZeneca from October 2008 to April 2011, where they focused on targeting DNA damage and repair in cancer treatment.

Earlier in their career, Xavier worked as a Senior Scientist at Lectus Therapeutics from November 2006 to September 2008, and as a project leader at Hybrigenics SA from 2002 to 2006.

Xavier Jacq completed their Bachelor's Degree in Biochemistry, Biophysics, and Molecular Biology at the University of Montpellier from 1988 to 1992. Xavier then pursued further education and obtained their PhD in Biochemistry from Université Louis Pasteur (Strasbourg I) between 1993 and 1997. Following this, Xavier went on to complete a PostDoc at Columbia University from 1997 to 2000, specializing in Oncology with a focus on p53-mdm2.